Key facts
- Elonova’s last known valuation is $2.9M (Dec 2025).
- Notable investors include Mirae Science and Technology.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Elonova
- ·The full record, as it builds
Funding rounds
No funding rounds for Elonova are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Elonova
Operator of an mRNA platform intended to improve the performance and manufacturability of vaccines and therapeutic RNA. The company offers proprietary MSCap technology with dual-modified nucleosides, engineered RNA ends, and scalable GMP manufacturing processes, enabling vaccine and therapeutic mRNA developers to achieve higher protein expression, lower immune activation, and reliable production.
- Sector
- Healthcare
- HQ
- Jeonbuk, South Korea
- Founded
- 2025
- Employees
- 3
- Website
- elonova.bio/
- Ownership
- Privately Held (backing)
Elonova doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Elonova shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Elonova in its N-PORT filings yet. We sweep new filings monthly.